Abstract: Background: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential…
Condition: Huntington’s Disease
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Abstract Anecdotal evidence that cannabis preparations have medical benefits together with the discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated efforts to develop cannabinoid-based therapeutics. These efforts have been…
Cannabinoids and neuroprotection in basal ganglia disorders
Cannabinoids have been proposed as clinically promising neuroprotective molecules, as they are capable to reduce excitotoxicity, calcium influx, and oxidative injury. They are also able to decrease inflammation by acting…
Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington’s disease transgenic mice
Loss of cannabinoid receptors (CB1) occurs prior to neurodegeneration in Huntington’s disease (HD). The levels and distribution of CB1 RNA were equivalent in 3-week-old mice regardless of genotype demonstrating that…
The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABAa receptor alterations in the human basal ganglia in Huntington’s disease
In order to investigate the sequence and pattern of neurodegeneration in Huntington’s disease, the distribution and density of cannabinoid CB1, dopamine D1 and D2, adenosine A2a and GABAA receptor changes…